Biologic Therapeutic Drugs Market Report

Biologic Therapeutic Drugs Market - Global Professional Analysis and Forecast to 2026

  • POSTDATE：Oct 19, 2019
  • PAGES：154
  • REPORT CODE：GMM332845
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The worldwide Biologic Therapeutic Drugs market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 6.0% during the forecast period.

    This report presents the market size and development trends by detailing the Biologic Therapeutic Drugs market revenue, market share and growth rate from 2015-2026, and it gives a thorough analysis by various product types, applications, regions, and main participants. The market conditions (2015-2019), corporate competition pattern, corporate SWOT analysis are elaborated, and other qualitative analyses like market dynamics, market penetration, market business environment analyses, the regional regulatory scenario in the Biologic Therapeutic Drugs market will be shown in this report. In short, this report will comprehensively reveal the characteristics of Biologic Therapeutic Drugs industry and will help you to build a panoramic view of the industrial development.

    Biologic Therapeutic Drugs Market, By Type:

    • Type 1

    • Type 2

    • Type 3

    Biologic Therapeutic Drugs Market, By Application:

    • End-Users 1

    • End-Users 2

    • End-Users 3

    Some of the leading players are as follows:

    • ABBVIE

    • GENZYME

    • ADVAXIS

    • ERYTECH PHARMA

    • AGENNIX AG

    • ELI LILLY & CO

    • AKEBIA THERAPEUTICS

    • HELIX BIOPHARMA

    • BAYER SCHERING PHARMA AG

    • BAXTER BIOSCIENCE

    • ABBOTT LABORATORIES

    • GLYCOTOPE GMBH

    • BIOVITRUM AB

    • H LUNDBECK A/S

    • H. LUNDBECK A/S

    • BIOINVENT INTERNATIONAL AB

    • DYAX

    • DENDREON

    • CSL BEHRING

    • DEBIOPHARM

    • CHUGAI PHARMACEUTICALS.

    • APOGENIX

    • GENENTECH

    • HAWAII BIOTECH

    • CELLDEX THERAPEUTICS

    • BIOGEN IDEC

    • AMGEN

    • APTALIS PHARMACEUTICAL

    • CHINA BIOLOGIC PRODUCTS

    • GENMAB A/S

    Geographically, Major regions are analyzed in details are as follows:

    • North America

    • Europe

    • Asia Pacific

    • Latin America

    • Middle East & Africa

  • Table of Contents

    1 Methodology and Scope

    • 1.1 Market Segmentation & Scope

      • 1.1.1 Technology Type

      • 1.1.2 Product

      • 1.1.3 Application

      • 1.1.4 Regional scope

      • 1.1.5 Estimates and forecast timeline

    • 1.2 Research Methodology

    • 1.3 Information Procurement

      • 1.3.1 Purchased database

      • 1.3.2 Internal database

      • 1.3.3 Secondary sources

      • 1.3.4 Primary research

      • 1.3.5 Details of primary research

    • 1.4 Information or Data Analysis

      • 1.4.1 Data analysis models

    • 1.5 Market Formulation & Validation

    • 1.6 Model Details

      • 1.6.1 Commodity flow analysis

      • 1.6.2 Volume price analysis

    • 1.7 List of Secondary Sources

    • 1.8 List of Abbreviations

    2 Executive Summary

    • 2.1 Market Outlook

    • 2.2 Segment Outlook

    3 Market Variables, Trends, & Scope

    • 3.1 Market Lineage Outlook

    • 3.1.1 Parent market outlook

      • 3.1.2 Ancillary market outlook

    • 3.2 Market Segmentation

      • 3.2.1 Analysis

    • 3.3 Market Dynamics

      • 3.3.1 Market driver analysis

      • 3.3.2 Market restraint analysis

      • 3.3.3 Industry opportunities

    • 3.4 Penetration & Growth Prospect Mapping

      • 3.4.1 Penetration & growth prospect mapping analysis

    • 3.5 Business Environment Analysis Tools

      • 3.5.1 Porter's five forces analysis

      • 3.5.2 PESTLE analysis

      • 3.5.3 Major deals & strategic alliances analysis

    4 Biologic Therapeutic Drugs Market: Technology Type Analysis

    • 4.1 Biologic Therapeutic Drugs Technology Type Market Share Analysis, 2018 & 2026

    • 4.2 Biologic Therapeutic Drugs Technology Type Market: Segment Dashboard

    • 4.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Technology Type Segment

      • 4.3.1 Type 1

      • 4.3.2 Type 2

      • 4.3.3 Type 3

    5 Biologic Therapeutic Drugs Market: Product Analysis

    • 5.1 Biologic Therapeutic Drugs Product Market Share Analysis, 2018 & 2026

    • 5.2 Biologic Therapeutic Drugs Product Market: Segment Dashboard

    • 5.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Product Segment

    6 Biologic Therapeutic Drugs Market: Application Analysis

    • 6.1 Biologic Therapeutic Drugs Application Market Share Analysis, 2018 & 2026

    • 6.2 Biologic Therapeutic Drugs Application Market: Segment Dashboard

    • 6.3 Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the Application Segment

      • 6.3.1 End-User 1

      • 6.3.2 End-User 1

      • 6.3.3 End-User 3

    7 Biologic Therapeutic Drugs Market: Regional Analysis

    • 7.1 Biologic Therapeutic Drugs Regional Market Share Analysis, 2018 & 2026

    • 7.2 Biologic Therapeutic Drugs Regional Market: Segment Dashboard

    • 7.3 Regional Market Snapshot (Market Size, CAGR, Top Countries)

    • 7.4 List of Players at Regional Level

      • 7.4.1 North America

      • 7.4.2 Europe

      • 7.4.3 Asia Pacific

    • 7.5 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)

      • 7.5.1 North America

      • 7.5.2 Europe

      • 7.5.3 Asia Pacific

      • 7.5.4 Latin America

      • 7.5.5 MEA

    • 7.6 Market Size & Forecasts, and Trend Analysis, 2015 to 2026

      • 7.6.1 North America

      • 7.6.2 Europe

      • 7.6.3 Asia Pacific

      • 7.6.4 Latin America

      • 7.6.5 Middle East & Africa

    8 Competitive Analysis

    • 8.1 Recent Developments & Impact Analysis, by Key Market Participants

    • 8.2 Strategic Framework/Competition Categorization (Key innovators, Market leaders, Emerging players)

    • 8.3 Vendor Landscape

      • 8.3.1 Company market position analysis (Geographic presence, service portfolio, strategic initiatives)

    9 Company Profiles

    • 9.1 ABBVIE

      • 9.1.1 ABBVIE Company overview

      • 9.1.2 Financial performance

      • 9.1.3 Product benchmarking

      • 9.1.4 Strategic initiatives

      • 9.1.5 SWOT analysis

    • 9.2 GENZYME

      • 9.2.1 GENZYME Company overview

      • 9.2.2 Financial performance

      • 9.2.3 Product benchmarking

      • 9.2.4 Strategic initiatives

      • 9.2.5 SWOT analysis

    • 9.3 ADVAXIS

      • 9.3.1 ADVAXIS Company overview

      • 9.3.2 Financial performance

      • 9.3.3 Product benchmarking

      • 9.3.4 Strategic initiatives

      • 9.3.5 SWOT analysis

    • 9.4 ERYTECH PHARMA

      • 9.4.1 ERYTECH PHARMA Company overview

      • 9.4.2 Financial performance

      • 9.4.3 Product benchmarking

      • 9.4.4 Strategic initiatives

      • 9.4.5 SWOT analysis

    • 9.5 AGENNIX AG

      • 9.5.1 AGENNIX AG Company overview

      • 9.5.2 Financial performance

      • 9.5.3 Product benchmarking

      • 9.5.4 Strategic initiatives

      • 9.5.5 SWOT analysis

    • 9.6 ELI LILLY & CO

      • 9.6.1 ELI LILLY & CO Company overview

      • 9.6.2 Financial performance

      • 9.6.3 Product benchmarking

      • 9.6.4 Strategic initiatives

      • 9.6.5 SWOT analysis

    • 9.7 AKEBIA THERAPEUTICS

      • 9.7.1 AKEBIA THERAPEUTICS Company overview

      • 9.7.2 Financial performance

      • 9.7.3 Product benchmarking

      • 9.7.4 Strategic initiatives

      • 9.7.5 SWOT analysis

    • 9.8 HELIX BIOPHARMA

      • 9.8.1 HELIX BIOPHARMA Company overview

      • 9.8.2 Financial performance

      • 9.8.3 Product benchmarking

      • 9.8.4 Strategic initiatives

      • 9.8.5 SWOT analysis

    • 9.9 BAYER SCHERING PHARMA AG

      • 9.9.1 BAYER SCHERING PHARMA AG Company overview

      • 9.9.2 Financial performance

      • 9.9.3 Product benchmarking

      • 9.9.4 Strategic initiatives

      • 9.9.5 SWOT analysis

    • 9.10 BAXTER BIOSCIENCE

      • 9.10.1 BAXTER BIOSCIENCE Company overview

      • 9.10.2 Financial performance

      • 9.10.3 Product benchmarking

      • 9.10.4 Strategic initiatives

      • 9.10.5 SWOT analysis

    • 9.11 ABBOTT LABORATORIES

      • 9.11.1 ABBOTT LABORATORIES Company overview

      • 9.11.2 Financial performance

      • 9.11.3 Product benchmarking

      • 9.11.4 Strategic initiatives

      • 9.11.5 SWOT analysis

    • 9.12 GLYCOTOPE GMBH

      • 9.12.1 GLYCOTOPE GMBH Company overview

      • 9.12.2 Financial performance

      • 9.12.3 Product benchmarking

      • 9.12.4 Strategic initiatives

      • 9.12.5 SWOT analysis

    • 9.13 BIOVITRUM AB

      • 9.13.1 BIOVITRUM AB Company overview

      • 9.13.2 Financial performance

      • 9.13.3 Product benchmarking

      • 9.13.4 Strategic initiatives

      • 9.13.5 SWOT analysis

    • 9.14 H LUNDBECK A/S

      • 9.14.1 H LUNDBECK A/S Company overview

      • 9.14.2 Financial performance

      • 9.14.3 Product benchmarking

      • 9.14.4 Strategic initiatives

      • 9.14.5 SWOT analysis

    • 9.15 H. LUNDBECK A/S

      • 9.15.1 H. LUNDBECK A/S Company overview

      • 9.15.2 Financial performance

      • 9.15.3 Product benchmarking

      • 9.15.4 Strategic initiatives

      • 9.15.5 SWOT analysis

    • 9.16 BIOINVENT INTERNATIONAL AB

      • 9.16.1 BIOINVENT INTERNATIONAL AB Company overview

      • 9.16.2 Financial performance

      • 9.16.3 Product benchmarking

      • 9.16.4 Strategic initiatives

      • 9.16.5 SWOT analysis

    • 9.17 DYAX

      • 9.17.1 DYAX Company overview

      • 9.17.2 Financial performance

      • 9.17.3 Product benchmarking

      • 9.17.4 Strategic initiatives

      • 9.17.5 SWOT analysis

    • 9.18 DENDREON

      • 9.18.1 DENDREON Company overview

      • 9.18.2 Financial performance

      • 9.18.3 Product benchmarking

      • 9.18.4 Strategic initiatives

      • 9.18.5 SWOT analysis

    • 9.19 CSL BEHRING

      • 9.19.1 CSL BEHRING Company overview

      • 9.19.2 Financial performance

      • 9.19.3 Product benchmarking

      • 9.19.4 Strategic initiatives

      • 9.19.5 SWOT analysis

    • 9.20 DEBIOPHARM

      • 9.20.1 DEBIOPHARM Company overview

      • 9.20.2 Financial performance

      • 9.20.3 Product benchmarking

      • 9.20.4 Strategic initiatives

      • 9.20.5 SWOT analysis

    • 9.21 CHUGAI PHARMACEUTICALS.

      • 9.21.1 CHUGAI PHARMACEUTICALS. Company overview

      • 9.21.2 Financial performance

      • 9.21.3 Product benchmarking

      • 9.21.4 Strategic initiatives

      • 9.21.5 SWOT analysis

    • 9.22 APOGENIX

      • 9.22.1 APOGENIX Company overview

      • 9.22.2 Financial performance

      • 9.22.3 Product benchmarking

      • 9.22.4 Strategic initiatives

      • 9.22.5 SWOT analysis

    • 9.23 GENENTECH

      • 9.23.1 GENENTECH Company overview

      • 9.23.2 Financial performance

      • 9.23.3 Product benchmarking

      • 9.23.4 Strategic initiatives

      • 9.23.5 SWOT analysis

    • 9.24 HAWAII BIOTECH

      • 9.24.1 HAWAII BIOTECH Company overview

      • 9.24.2 Financial performance

      • 9.24.3 Product benchmarking

      • 9.24.4 Strategic initiatives

      • 9.24.5 SWOT analysis

    • 9.25 CELLDEX THERAPEUTICS

      • 9.25.1 CELLDEX THERAPEUTICS Company overview

      • 9.25.2 Financial performance

      • 9.25.3 Product benchmarking

      • 9.25.4 Strategic initiatives

      • 9.25.5 SWOT analysis

    • 9.26 BIOGEN IDEC

      • 9.26.1 BIOGEN IDEC Company overview

      • 9.26.2 Financial performance

      • 9.26.3 Product benchmarking

      • 9.26.4 Strategic initiatives

      • 9.26.5 SWOT analysis

    • 9.27 AMGEN

      • 9.27.1 AMGEN Company overview

      • 9.27.2 Financial performance

      • 9.27.3 Product benchmarking

      • 9.27.4 Strategic initiatives

      • 9.27.5 SWOT analysis

    • 9.28 APTALIS PHARMACEUTICAL

      • 9.28.1 APTALIS PHARMACEUTICAL Company overview

      • 9.28.2 Financial performance

      • 9.28.3 Product benchmarking

      • 9.28.4 Strategic initiatives

      • 9.28.5 SWOT analysis

    • 9.29 CHINA BIOLOGIC PRODUCTS

      • 9.29.1 CHINA BIOLOGIC PRODUCTS Company overview

      • 9.29.2 Financial performance

      • 9.29.3 Product benchmarking

      • 9.29.4 Strategic initiatives

      • 9.29.5 SWOT analysis

    • 9.30 GENMAB A/S

      • 9.30.1 GENMAB A/S Company overview

      • 9.30.2 Financial performance

      • 9.30.3 Product benchmarking

      • 9.30.4 Strategic initiatives

      • 9.30.5 SWOT analysis

     

    The List of Tables and Figures (Totals 71 Figures and 128 Tables)

    • Figure Type 1 Biologic Therapeutic Drugs market, 2015 - 2026 (USD Million)

    • Figure Type 2 Biologic Therapeutic Drugs market, 2015 - 2026 (USD Million)

    • Figure Type 3 Biologic Therapeutic Drugs market, 2015 - 2026 (USD Million)

    • Figure End-Users 1 market, 2015 - 2026 (USD Million)

    • Figure End-Users 2 market, 2015 - 2026 (USD Million)

    • Figure End-Users 3 market, 2015 - 2026 (USD Million)

    • Table List of players in North America

    • Table List of players in Europe

    • Table List of players in Asia Pacific

    • Table SWOT analysis

    • Table North America Biologic Therapeutic Drugs market, by country, 2015 - 2026 (USD Million)

    • Table North America Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table North America Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table North America Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.S. Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table U.S. Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table U.S. Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Canada Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Canada Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Canada Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Europe Biologic Therapeutic Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Europe Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Europe Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Europe Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table U.K. Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table U.K. Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table U.K. Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Germany Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Germany Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Germany Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table France Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table France Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table France Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Italy Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Italy Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Italy Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Spain Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Spain Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Spain Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Asia Pacific Biologic Therapeutic Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Asia Pacific Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Asia Pacific Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Asia Pacific Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table China Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table China Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table China Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Japan Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Japan Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Japan Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table India Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table India Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table India Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Latin America Biologic Therapeutic Drugs market, by country, 2015 - 2026 (USD Million)

    • Table Latin America Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Latin America Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Latin America Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Brazil Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Brazil Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Brazil Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Mexico Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Mexico Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Mexico Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Argentina Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Argentina Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Argentina Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table MEA Biologic Therapeutic Drugs market, by country, 2015 - 2026 (USD Million)

    • Table MEA Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table MEA Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table MEA Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table South Africa Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table South Africa Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table South Africa Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Regulatory scenario

    • Table Nigeria Biologic Therapeutic Drugs market, by type, 2015 - 2026 (USD Million)

    • Table Nigeria Biologic Therapeutic Drugs market, by product, 2015 - 2026 (USD Million)

    • Table Nigeria Biologic Therapeutic Drugs market, by application, 2015 - 2026 (USD Million)

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Recent Developments & Impact Analysis, by Key Market Participants

    • Table Company market position analysis

    • Table Company Profiles

    • Table ABBVIE Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GENZYME Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table ADVAXIS Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table ERYTECH PHARMA Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AGENNIX AG Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table ELI LILLY & CO Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AKEBIA THERAPEUTICS Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table HELIX BIOPHARMA Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BAYER SCHERING PHARMA AG Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BAXTER BIOSCIENCE Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table ABBOTT LABORATORIES Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GLYCOTOPE GMBH Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BIOVITRUM AB Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table H LUNDBECK A/S Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table H. LUNDBECK A/S Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BIOINVENT INTERNATIONAL AB Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table DYAX Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table DENDREON Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CSL BEHRING Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table DEBIOPHARM Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CHUGAI PHARMACEUTICALS. Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table APOGENIX Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GENENTECH Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table HAWAII BIOTECH Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CELLDEX THERAPEUTICS Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table BIOGEN IDEC Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table AMGEN Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table APTALIS PHARMACEUTICAL Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table CHINA BIOLOGIC PRODUCTS Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

    • Table Company Profiles

    • Table GENMAB A/S Production, Value, Price, Gross Margin 2014-2019

    • Table Product benchmarking

    • Table Strategic initiatives

    • Table SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US